Our study underscores the strong association between improved cardiometabolic health and survival following MI, highlighting the effectiveness of SGLT2 inhibitors across the post-MI spectrum and identifying T2DM as a key factor mediating their benefit. Here, SLC5A2 is linked to type 2 diabetes mellitus.